Mufemilast vs PALI-2108
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: PDE4 · full Ulcerative Colitis pipeline
Mufemilast
Marketed by Tianjin Hemay Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05486104 (registry estimate)
No aligned efficacy figure on record for this race.
PALI-2108
Developed by Palisade Bio
NCT06663605 · Phase 1 · completed
Most of this study randomized healthy volunteers to PALI-2108 or matching placebo under double-blind conditions, though the ulcerative colitis patient cohort was open-label. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ]". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: October 2027 · NCT07845487 (registry estimate)
Reported efficacy
Incidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ] (SAD and FE Phase: [ Day 1 to Day 7 ], MAD and UC Phase: [ Days 1 to Day 28 ]): Phase 1a: the study met its primary endpoints of safety, tolerability and pharmacokinetics, with no serious adverse events and no treatment-emergent adverse events related to laboratory values or EKGs across the single and multiple ascending dose cohorts. In the single-dose study (15 to 450 mg) only mild, reversible treatment-emergent adverse events occurred, limited to the 450 mg dose. Multiple-dose cohorts (15, 30 and 50 mg twice daily over 7 days, and 30 mg titrated over 7 days) showed mostly minor events, with one moderate event at 50 mg twice daily leading to withdrawal. (not_applicable)
Result source: NCT06663605
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Mufemilast | PALI-2108 |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT07650942 | —Not reported |
| Clinical remission (maintenance) | —Trial running · NCT07650942 | —Not reported |
| Clinical response (induction) | —Trial running · NCT07650942 | —Not reported |
| Endoscopic improvement (induction) | —Trial running · NCT07650942 | —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT07650942 | —Not reported |
Clinical remission (induction)
- Mufemilast
- —Trial running · NCT07650942
- PALI-2108
- —Not reported
Clinical remission (maintenance)
- Mufemilast
- —Trial running · NCT07650942
- PALI-2108
- —Not reported
Clinical response (induction)
- Mufemilast
- —Trial running · NCT07650942
- PALI-2108
- —Not reported
Endoscopic improvement (induction)
- Mufemilast
- —Trial running · NCT07650942
- PALI-2108
- —Not reported
Corticosteroid-free remission (maintenance)
- Mufemilast
- —Trial running · NCT07650942
- PALI-2108
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Mufemilast: no structured comparison results are available for Ulcerative Colitis.
PALI-2108: no structured comparison results are available for Ulcerative Colitis.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mufemilast's landscape · PALI-2108's landscape